[go: up one dir, main page]

WO2001064209A1 - Procede d'identification d'un agent pour le traitement du diabete dnid par interaction avec un compose uo126 - Google Patents

Procede d'identification d'un agent pour le traitement du diabete dnid par interaction avec un compose uo126 Download PDF

Info

Publication number
WO2001064209A1
WO2001064209A1 PCT/SE2001/000450 SE0100450W WO0164209A1 WO 2001064209 A1 WO2001064209 A1 WO 2001064209A1 SE 0100450 W SE0100450 W SE 0100450W WO 0164209 A1 WO0164209 A1 WO 0164209A1
Authority
WO
WIPO (PCT)
Prior art keywords
glucose
insulin
cells
target polypeptide
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE2001/000450
Other languages
English (en)
Inventor
Marguerite Luthman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Swedish Orphan Biovitrum AB
Original Assignee
Biovitrum AB
Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum AB, Pharmacia AB filed Critical Biovitrum AB
Priority to JP2001563106A priority Critical patent/JP2003525431A/ja
Priority to CA002399889A priority patent/CA2399889A1/fr
Priority to EP01912628A priority patent/EP1259232A1/fr
Priority to AU2001241316A priority patent/AU2001241316A1/en
Publication of WO2001064209A1 publication Critical patent/WO2001064209A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose

Definitions

  • the present invention relates to the use of 1 ,4-diamino-2,3-dicyano-l ,4-bis [2- aminophenylthio] butadiene (U0126) in methods for identification of agents useful in the treatment of medical conditions related to reduced cellular uptake of glucose, in particular type II diabetes.
  • Insulin One of the major hormones that influence metabolism is insulin, which is synthesized in the beta cells of the islets of Langerhans of the pancreas. Insulin primarily regulates the direction of metabolism, shifting many processes toward the storage of substrates and away from their degradation. Insulin acts to increase the transport of glucose and amino acids as well as key minerals such as potassium, magnesium, and phosphate from the blood into cells. It also regulates a variety of enzymatic reactions within the cells, all of which have a common overall direction, namely the synthesis of large molecules from small units.
  • a deficiency in the action of insulin causes severe impairment in (i) the storage of glucose in the form of glycogen and the oxidation of glucose for energy; (ii) the synthesis and storage of fat from fatty acids and their precursors and the completion of fatty-acid oxidation; and (iii) the synthesis of proteins from amino acids.
  • Type I diabetes insulin-dependent diabetes mellitus (EDDM), for which insulin injection is required; it was formerly referred to as juvenile onset diabetes. In this type, insulin is not secreted by the pancreas and hence must be taken by injection.
  • Type II diabetes non-insulin-dependent diabetes mellitus (NIDDM ). is characterized clinically by hyperglycemia and insulin resistance and is commonly associated with obesity.
  • Type II diabetes is a heterogeneous group of disorders in which hyperglycemia results from both an impaired insulin secretory response to glucose and decreased insulin effectiveness in stimulating glucose uptake by skeletal muscle and in restraining hepatic glucose production (insulin resistance)
  • insulin resistance hepatic glucose production
  • patients Before diabetes develops, patients generally lose the early insulin secretory response to glucose and may secrete relatively large amounts of proinsuhn
  • fasting plasma insulin levels may be normal or even increased in type II diabetes patients, glucose- stimulated insulin secretion is clearly decreased The decreased insulin levels reduce insulin-mediated glucose uptake and fail to restrain hepatic glucose production
  • Glucose homeostasis depends upon a balance between glucose production by the liver and glucose utilization by insulin-dependent tissues, such as fat and muscle, and lnsulin- independent tissues, such as brain and kidney In type II diabetes, the entiy of glucose into fat and muscle is reduced and glucose production in the livei is increased, due to insulin resistance in the tissues
  • insulin acts as a stimulator of cell growth and protein synthesis
  • IR insulin receptor
  • IRS 1/2 insulin receptor substrates 1/2
  • PI 3-K phosphoinositide 3-k ⁇ nase
  • Wortmannin an antibiotic isolated from Penicilhum ⁇ wortmanni
  • PI 3- kinase A cross-talk between PI3-K in the carbohydrate pathway and MEK/ERK in the mitogemc pathway has been identified
  • wortmannin has been shown to increase the MEK/ERK signaling in the mitogen-activated cascade
  • a commonly used inhibitor for the MAPK signaling pathway is PD98059 (2-Amino-3- methoxyflavone), which inhibits activation (phosphorylation) of inactive MEK1/ 2 (cf. Fig. 1 ).
  • the compound U0126 ( 1.4-diamino-2,3-dicyano-l ,4-bis [2-aminophenylthio] butadiene) has recently been shown to be a MAPK inhibitor (Favata M F et al. (1998) J. Biol. Chem. 273: 18623-18632: Goueli, S.A. et al. (1998) Promega Notes 69, p.6). U0126 specifically inhibits MEK1/2 in both the inactive and active forms. This is in contrast to PD98059, which only inhibits phosphorylation of inactive MEK1/ 2 (Favata et al., supra; cf. Fig. 1).
  • protein kinase inhibitors see e.g. Davies, S.P. et al. (2000) Biochem. J. 351 : 95-105.
  • the compound U0126 has been identified as an inhibitor of AP-1 transactivation in a cell-based reporter assay used to screen for an anti-inflammatory drugs (Duncia, JN. et al. (1998) Bioorganic & Medicinal Chemistry Letters 8: 2839-2844).
  • Antagonism of the transcription factor AP-1 and ⁇ F-kappa B which are important regulators of immune response genes, has been demonstrated to be the primary mechanism for the anti- inflammatory and immune suppressive effects of steroids.
  • U0126 was also shown to inhibit, in fibroblasts, genes containing AP- 1 response element in their promoters. These effects of U0126 result from direct inhibition of MEK1/2. Activation of this pathway regulates the activity of a number of substrates through phosphorylation.
  • Fig. 1 Scheme of the insulin signaling pathways leading to glucose uptake and protein synthesis. Black bars indicate inhibitory activities. For further details, see the background art section.
  • Fig. 2 Glucose uptake rate in rat skeletal muscle cells.
  • Fig. 3 Glucose uptake rate in human skeletal muscle cells.
  • Fig. 4 Glucose uptake rate in human neuroblastoma cells. "Wo” is abbreviation for wortmannin.
  • Fig. 5 Glucose oxidation in rat skeletal muscle cells.
  • Fig. 6 Palmitate oxidation in rat skeletal muscle cells during insulin resistant conditions.
  • Fig. 7 PKB activity in rat skeletal muscle cells.
  • Fig. 8 Insulin secretion in rat insulinoma cells.
  • the compound l,4-diamino-2,3-dicyano-l,4-bis [2- aminophenylthio] butadiene controls glucose homeostasis in cell lines from different species.
  • U0126 increases glucose transport and glucose oxidation and decreases fatty acid oxidation in the rat skeletal muscle cell line L6 during normal and insulin resistant conditions (Figs. 2, 5 and 6).
  • U0126 also increases glucose transport in human skeletal muscle cells (Fig. 3) and in a human neuroblastoma cell line, SH-SY5Y (Fig. 4).
  • U0126 stimulates insulin secretion in a rat insulinoma cell line, INS-1 (Fig. 8).
  • the present invention thus relates to the use of l,4-diamino-2,3-dicyano-l,4-bis [2- aminophenylthio] butadiene (U0126) in methods for identification of agents useful in the treatment of medical conditions related to reduced cellular uptake of glucose, in particular type II diabetes.
  • This invention also provides methods for identifying therapeutically useful agents having similar properties as U0126.
  • agents may be identified by reacting a target polypeptide, with a substance which potentially binds to the said target polypeptide, and assaying for substance-polypeptide complex, for free substance or for non-complexed target polypeptide, or for activation of the target polypeptide.
  • the substance- polypeptide complex, free substance or non-complexed target polypeptides may be isolated by conventional isolation techniques, e.g. salting out, chromatography, electrophoresis, gel filtration, fractionation, abso ⁇ tion, agglutination, or combinations thereof.
  • this invention provides a method for identifying an agent useful for the treatment or prevention of a medical condition related to reduced cellular uptake of glucose, said method comprising the steps of:
  • agent means a biological or chemical compound such as a simple or complex organic molecule, a peptide, or a protein.
  • the said medical condition related to reduced cellular uptake of glucose is, in particular, type II diabetes.
  • the said target polypeptide can be a kinase, in particular a kinase involved in the insulin signaling pathway, such as phosphoinositide 3-kinase (PI 3-kinase).
  • PI 3-kinase phosphoinositide 3-kinase
  • the skilled person will be able to determine whether U0126 binds to other polypeptides that are suitable for use in screening assays.
  • the interaction between the target polypeptide and the compound U0126 can be determined by methods known in the art. For instance, labeled U0126 can be used to determine binding to polypeptides involved in glucose metabolism and insulin signaling. Where a radioactive label is used as a detectable substance, the target polypeptide may be localized by autoradiography.
  • the compound U0126 can conveniently be used as a control substance for determining the effect of the candidate agent.
  • an effect similar to the effects of U0126 would be indicative that the candidate agent is useful for the treatment or prevention of a medical condition related to reduced cellular uptake of glucose.
  • Suitable methods, such as competition assays are known in the art, see e.g. Lutz, M. & Kenakin, T. "Quantitative Molecular Pharmacology and Informatics in Drug Discovery", John Wiley & Sons Ltd., 1999.
  • the invention provides the use of an agent, identified by the methods described above, in methods for treatment of a medical condition related to reduced glucose uptake.
  • the compositions or agents identified using the methods disclosed herein may be administered systemically, for example, formulated in a pharmaceutically acceptable buffer such as physiological saline.
  • a pharmaceutically acceptable buffer such as physiological saline.
  • routes of administration include, for example, oral, subcutaneous, intravenous, intraperitoneally, intramuscular, or intradermal injections, which provide continuous, sustained levels of the drug in the patient.
  • Treatment of human patients or other animals will be carried out using a therapeutically effective amount of an identified compound in a physiologically acceptable carrier. Suitable carriers and their formulation are described, for example, in Remington's Pharmaceutical Sciences by E. W. Martin.
  • the amount of the active compound to be administered varies depending upon the manner of administration, the age and body weight of the patient, and with the type of disease and extensiveness of the disease. Generally, amounts will be in the range of those used for other agents used in the
  • Rat skeletal muscle cells L6 were obtained from The American Type Culture Collection (ATCC). Human neuroblastoma cells, SH-SY5Y, were obtained from European Collection of Animal cell cultures (ECACC). Human skeletal muscle cells (hSkMC) were purchased from PromoCell, Germany.
  • the insulin-secreting cell line INS-1 isolated from rat insulinoma (Asfari et al. (1992) Endocrinology 130: 167-178) was obtained from Prof. C.B. Wollheim, University Medical Center, Geneva. Switzerland.
  • Bovine insulin Dulbecco's Modified Eagle's Medium (DMEM), RPMI 1640 medium, Phosphate Buffered Saline (PBS), HEPES, pyruvate, 2-mercaptoethanol.
  • Foetal Bovine Serum (FBS), penicillin and streptomycin (PEST) were purchased from Gibco Laboratories. Growth medium for hSkMC was purchased from PromoCell, Germany. Wortmannin and PD98059 were obtained from Alexis Biochemicals, San Diego, CA, USA.
  • U0126 was purchased from Promega Co ⁇ oration, Madison, WI, U.S.A. Tissue culture plates were purchased from Costar, U.S.A.
  • Bovine Serum Albumin (BSA), dexamethasone, IBMX, Tris HCl, EGTA, MgCl 2 , ATP, microcystin, sodium orthovanadate, sodium betaglycerophosphate, NaF, MOPS, DTT and protease inhibitors were obtained from Sigma. USA.
  • U- 1 C-glucose, H-2-deoxy-glucose, U- 1 C-palmitate and 33 P-ATP were from Du Pont NEN, Medical Scandinavia. Sweden. Whatman No.l filter papers and p81 phosphocellulose filter papers from Kebo Lab., Sweden, hyamine hydroxide from ICN, USA.
  • Anti-PKB ⁇ antibody pre-coupled to protein A beads was purchased from Upstate, USA, AGIO anti-phosphotyrosine antibody were bought from Santa Cruz Biotechnology, INC, USA, and goat anti-mouse horseradish peroxidase-coupled secondary antibody from DAKO, Denmark.
  • the protein concentrations in cell lysates were determined using a protein determination kit from Pierce, USA. Rat insulin was determined with an ELISA from Mercodia AB, Uppsala, Sweden.
  • Rat L6 myoblasts were grown in culture flasks in DMEM containing 10% FBS and 2% PEST. To initiate differentiation, the media of sub-confluent cell cultures were replaced with DMEM supplemented with 1 % FCS and 0.3 ⁇ M insulin as described in Klip, A. et al. (1984) Am. J. Physiol. 247: E291-E296 and Walker, P.S. et al. (1989) J. Biol. Chem. 264: 6587-6595. SHSY5Y cells were grown in DMEM containing 10% FBS. INS-1 cells were grown in RPMI 1640 medium supplemented with 10 mM HEPES, 1 mM pyruvate, 50 ⁇ M 2-mercaptoethanol and 5% FBS.
  • Glucose uptake was determined as described by Hundal et al. (1994) Biochem. J. 297: 289-295. Briefly, after incubation with insulin for one hour, cell monolayers were rinsed with glucose-free PBS. Glucose uptake was quantified by incubating the cells in the presence of 1 ⁇ Ci/ml 3 H-2-deoxy-glucose in PBS for 8 min. Uptake of 2-deoxy-glucose was terminated by rapidly aspirating the medium, followed by two successive washes of cell monolayers with ice cold PBS. The cells were lysed in 0.5 M NaOH, followed by liquid scintillation counting. Rates of transport were normalized for protein content in each well.
  • the principle of the used glucose/free fatty acids (FFA) oxidation assay is based on the fact that one of the final products along metabolic pathways of these two substrates is carbon dioxide. Since the substrates are uniformly 14 C labeled, the radioactivity in carbon dioxide trap is a direct measure of metabolic activity in studied cells (Rodbell, M. (1964) J. Biol. Chem. 239: 375-380).
  • the tube was mounted in the flasks, the screw caps were tightened and cells were incubated at 37°C for a suitable time period.
  • the reaction was terminated by adding sulfuric acid to the culture medium and the cells were incubated for additional 60 min.
  • the filter paper was removed, cut into small pieces and transferred to scintillation vials.
  • Methanol (0.2 ml) was added to each vial to increase the solubility of hyamine-CO2 in the scintillation fluid. Finally the radioactivity was measured.
  • the remaining cells were washed briefly with ice cold PBS, solubilized with 1 M KOH and the protein content was determined by the Bradford method (Bradford, M. M. (1976) Anal. Biochem. 72: 248-254).
  • Glucose uptake rate in L6 cells in the presence of 5 mM glucose, was determined.
  • the cells were incubated in serum-free medium supplemented with U0126 (10 ⁇ M), PD98059 (10 ⁇ M) or wortmannin (100 nM) for 20 h. Insulin (176 nM) was added 1 h before the determination of glucose uptake rate.
  • Glucose uptake was determined as described above. The results (Fig. 2) indicate that U0126 and insulin increased glucose uptake in L6 cells. When U0126 and insulin were incubated together there was no further increase compared to U0126 alone. Wortmannin inhibited the effect of U0126.
  • EXAMPLE 2 Glucose uptake rate in human skeletal muscle cells
  • Glucose uptake rate in human skeletal muscle cells was determined.
  • the cells were incubated in serum-free medium (PromoCell) for 2 h.
  • Insulin 176 nM
  • U0126 10 ⁇ M
  • the results indicate that U0126 and insulin increase glucose uptake in hSkMC.
  • Glucose uptake rate in SH-SY5Y cells in the presence of 5 mM glucose was determined. The cells were incubated in serum-free medium over night. Approximately 20 h later U0126 (10 ⁇ M), wortmannin (100 nM) or insulin (176 nM) were added, 1 h before the determination of glucose uptake rate. The results (Fig. 4) indicate that U0126 and insulin increased glucose uptake in SH-SY5Y cells. Wortmannin inhibited the effect of U0126 and insulin.
  • Glucose oxidation in L6 cells in the presence of 5 mM glucose was determined as described in "Experimental Methods". One hour prior to determination of glucose oxidation, insulin or U0126 was added to a concentration of 176 nM or 10 ⁇ M, respectively. The results (Fig. 5) indicate that U0126 and insulin increased glucose oxidation in L6 cells. A small increase was found when U0126 and insulin were incubated together.
  • EXAMPLE 5 Palmitate oxidation in L6 cells
  • insulin resistance can be provoked experimentally by raising the concentrations of glucose, fat or both in the medium, or by treating the cells with the cytokine Tumor Necrosis Factor alpha (TNF alpha) before insulin stimulation.
  • TNF alpha Tumor Necrosis Factor alpha
  • L6 skeletal muscle cells were incubated in serum-free medium supplemented with 12 mM glucose and 480 ⁇ M palmitate bound to BSA for 20 hours.
  • insulin or U0126 was added to a concentration of 176 nM or 10 ⁇ M, respectively. Palmitate oxidation was determined as described in "Experimental methods". Palmitate oxidation in cells is indicative of the use of fatty acids as energy and is reversed to glucose oxidation.
  • the results (Fig. 6) indicate that U0126, in contrast to insulin, decreased palmitate oxidation during insulin resistant conditions. Both U0126 and insulin decreased palmitate oxidation in the presence of 5 mM glucose (data not shown).
  • differentiated L6 cells were starved with serum- free medium for 18 h and incubated with U0126 and insulin for 10 min. After the incubation the cells were washed with ice-cold serum-free medium prior to lysis with a buffer comprising 50 mM Tris/HCl, 0.1 mM EGTA, 10 mM MgCl 2 , 100 ⁇ M ATP, 250 nM microcystin, 1 mM sodium orthovanadate, 10 mM sodium betaglycerophosphate, 40 mM NaF and protease inhibitors.
  • a buffer comprising 50 mM Tris/HCl, 0.1 mM EGTA, 10 mM MgCl 2 , 100 ⁇ M ATP, 250 nM microcystin, 1 mM sodium orthovanadate, 10 mM sodium betaglycerophosphate, 40 mM NaF and protease inhibitors.
  • Lysates were pre-cleared by centrifugation at 14,000 ⁇ m for 10 minutes at 4°C and stored at -70°C until analysis.
  • PKB was immunoprecipitated from cell lysate equivalent to 100 ⁇ g protein using a slurry of anti- PKB ⁇ antibody pre-coupled to protein A beads (equivalent to 200ng antibody per immunoprecipitation). Immunoprecipitation occurred for 18 hours at 4°C and beads were washed three times with buffer A containing 500 mM NaCl, once with lysis buffer alone and once with assay dilution buffer comprising 20 mM MOPS, 1 mM sodium orthovanadate, 25 mM sodium betaglycerophosphate and 1 mM DTT.
  • PKB activity was assayed in "buffer A” containing 2-5 ⁇ Ci P-ATP in the presence of 50 ⁇ M Crosstide Peptide substrate, a peptide with the amino acid composition GRPRTSSFAEG.
  • Peptide phosphorylation reactions were terminated by spotting 40 ⁇ l of 50 ⁇ l the reaction mixtures into p81 phosphocellulose filter papers, followed by washing with 0.75% phosphoric acid. Radioactivity was determined by liquid scintillation spectrometry. The results (Fig. 7) indicate that insulin increased PKB activity three-fold in the cells while U0126 had no effect.
  • EXAMPLE 7 Insulin secretion in INS-1 cells.
  • Insulin secretion in INS-1 cells was determined. INS- 1 cells were seeded in 24-well plates. Thirty minutes before assay the glucose concentration was decreased to 2.8 mM. After the incubation in low glucose medium, glucose (up to 16 mM) or U0126 (10 ⁇ M) were added. After 24 hours, samples were collected and analyzed in the rat insulin ELISA. The results (Fig. 8) indicate that U0126 increased insulin secretion in INS-1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention se rapporte à un procédé permettant d'identifier un agent servant au traitement ou à la prévention d'un état médical associé à une absorption cellulaire réduite de glucose, ce procédé consistant: (i) à identifier un polypeptide cible interagissant avec le composé U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophénylthio]butadiène); (ii) à mettre en contact un agent candidat avec ce polypeptide cible; et (iii) à déterminer si cet agent candidat module les activités biologiques du polypeptide cible, une telle modulation indiquant la présence d'un agent servant au traitement ou à la prévention d'un état médical associé à une absorption cellulaire réduite de glucose.
PCT/SE2001/000450 2000-03-03 2001-03-02 Procede d'identification d'un agent pour le traitement du diabete dnid par interaction avec un compose uo126 Ceased WO2001064209A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2001563106A JP2003525431A (ja) 2000-03-03 2001-03-02 化合物ｕ０１２６との相互作用により、ｎｉｄｄｍ−糖尿病を処置するための医薬の同定法
CA002399889A CA2399889A1 (fr) 2000-03-03 2001-03-02 Procede d'identification d'un agent pour le traitement du diabete dnid par interaction avec un compose uo126
EP01912628A EP1259232A1 (fr) 2000-03-03 2001-03-02 Procede d'identification d'un agent pour le traitement du diabete dnid par interaction avec un compose uo126
AU2001241316A AU2001241316A1 (en) 2000-03-03 2001-03-02 Method for identifying an agent for treatment of niddmdiabetes by interaction with compound u0126

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0000718-7 2000-03-03
SE0000718A SE0000718D0 (sv) 2000-03-03 2000-03-03 New use

Publications (1)

Publication Number Publication Date
WO2001064209A1 true WO2001064209A1 (fr) 2001-09-07

Family

ID=20278690

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2001/000450 Ceased WO2001064209A1 (fr) 2000-03-03 2001-03-02 Procede d'identification d'un agent pour le traitement du diabete dnid par interaction avec un compose uo126

Country Status (6)

Country Link
EP (1) EP1259232A1 (fr)
JP (1) JP2003525431A (fr)
AU (1) AU2001241316A1 (fr)
CA (1) CA2399889A1 (fr)
SE (1) SE0000718D0 (fr)
WO (1) WO2001064209A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053927A1 (fr) * 1998-04-17 1999-10-28 Trustees Of Tufts College Procedes pour traiter et prevenir la resistance a l'insuline et les troubles qui y sont lies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053927A1 (fr) * 1998-04-17 1999-10-28 Trustees Of Tufts College Procedes pour traiter et prevenir la resistance a l'insuline et les troubles qui y sont lies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DUARTE C.B. ET AL.: "Protective role of neurotrophins against glutamate toxicity in cultured hippocampal neurons: signaling mechanisms", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 26, 2000, XP002943071 *
JOHN V. DUNCIA ET AL.: "Mek inhibitors: The chemistry and biological activity of U0126, its analogs and cyclization products", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 8, 1998, pages 2839 - 2844, XP004139571 *
MARGARET F. FAVATA ET AL.: "Identification of a novel inhibitor of mitogen-activated protein kinase", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 29, 1998, pages 18623 - 18632, XP002141538 *
STEPHEN D. DAVIES ET AL.: "Specificity and mechanism of action of some commonly used protein kinase inhibitors", BIOL. CHEM. JOURNAL, vol. 351, 2000, pages 95 - 105, XP000979108 *

Also Published As

Publication number Publication date
CA2399889A1 (fr) 2001-09-07
SE0000718D0 (sv) 2000-03-03
AU2001241316A1 (en) 2001-09-12
EP1259232A1 (fr) 2002-11-27
JP2003525431A (ja) 2003-08-26

Similar Documents

Publication Publication Date Title
Saxena et al. Leptin as a novel profibrogenic cytokine in hepatic stellate cells: mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (Erk) and Akt phosphorylation
Shah et al. Acute attenuation of translation initiation and protein synthesis by glucocorticoids in skeletal muscle
Samad et al. Insulin continues to induce plasminogen activator inhibitor 1 gene expression in insulin-resistant mice and adipocytes
Sung et al. Tumor necrosis factor-α inhibits peroxisome proliferator-activated receptor γ activity at a posttranslational level in hepatic stellate cells
Kumar et al. Development of insulin resistance and reversal by thiazolidinediones in C2C12 skeletal muscle cells
Du et al. The protective effects of lixisenatide against inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes
US20100120662A1 (en) Glucose uptake modulator and method for treating diabetes or diabetic complications
Öztürk Akcora et al. Pharmacological inhibition of STAT3 pathway ameliorates acute liver injury in vivo via inactivation of inflammatory macrophages and hepatic stellate cells
US20100297761A1 (en) Novel Use of Liver X Receptor Agonists
WO1996034943A1 (fr) 12-lipoxygenase leucocytaire humaine et son role dans la pathogenese d'etats pathologiques
Nacci et al. Infliximab therapy restores adiponectin expression in perivascular adipose tissue and improves endothelial nitric oxide-mediated vasodilation in mice with type 1 diabetes
Wang et al. Astragaloside III activates TACE/ADAM17‐dependent anti‐inflammatory and growth factor signaling in endothelial cells in a p38‐dependent fashion
CN106132413A (zh) IKKε/TBK1抑制剂与β肾上腺素能激动剂或交感神经系统激活剂的组合
Fain et al. Insulin enhances vascular endothelial growth factor, interleukin-8, and plasminogen activator inhibitor 1 but not interleukin-6 release by human adipocytes
US20150224089A1 (en) COMBINATIONS OF IKKi/TBK1 INHIBITORS WITH BETA ADRENERGIC AGONISTS OR SYMPATHETIC NERVOUS SYSTEM ACTIVATORS
Pei et al. Downregulation of chemerin and alleviation of endoplasmic reticulum stress by metformin in adipose tissue of rats
US6893829B2 (en) Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states
Andreozzi et al. Glucagon induces the hepatic expression of inflammatory markers in vitro and in vivo
WASMEIER et al. Secretagogue-dependent phosphorylation of phogrin, an insulin granule membrane protein tyrosine phosphatase homologue
Kleinert et al. An amino acid mixture enhances insulin-stimulated glucose uptake in isolated rat epitrochlearis muscle
US20010019832A1 (en) Methods for identification using U0126
Lee et al. Role of inositol-requiring enzyme 1 and autophagy in the pro-fibrotic mechanism underlying Graves’ orbitopathy
WO2001064209A1 (fr) Procede d'identification d'un agent pour le traitement du diabete dnid par interaction avec un compose uo126
Yoshii et al. Mechanism for distribution of acotiamide, a novel gastroprokinetic agent for the treatment of functional dyspepsia, in rat stomach
Shih et al. Anti-proliferation effect of 5, 5-diphenyl-2-thiohydantoin (DPTH) in human vascular endothelial cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001912628

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001241316

Country of ref document: AU

Ref document number: 2399889

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 521006

Country of ref document: NZ

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 563106

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2001912628

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001912628

Country of ref document: EP